Danaher (NYSE:DHR) kicked off 2025 with a robust first-quarter performance, delivering results that exceeded expectations across revenue, profit, and cash flow, sending its shares 6% higher intra-day today.
Adjusted earnings per share came in at $1.88, well above the $1.62 anticipated by analysts. Revenue reached $5.74 billion, topping projections of $5.56 billion. Operating profit also impressed at $1.27 billion, outperforming the $1.1 billion consensus.
The strong quarter was fueled by continued strength in the company’s bioprocessing segment and better-than-expected demand in molecular diagnostics, particularly related to respiratory testing. These areas helped offset broader macro uncertainties and demonstrated the resilience of Danaher’s portfolio.
Looking ahead, the company projects modest core revenue growth in the low single digits for the second quarter. For the full year, Danaher maintained its guidance, forecasting earnings per share between $7.60 and $7.75, aligning closely with the current analyst consensus. Core revenue growth is expected to be around 3% for the year.
